Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Daisuke Takahari, Hirokazu Shoji, Hiroki Hara, Taito Esaki, Nozomu Machida, Kengo Nagashima, Kazunori Aoki, Kazufumi Honda, Takahiro Miyamoto, Narikazu Boku, Ken Kato
Title Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).
Journal J Clin Oncol
Abstract Text J Clin Oncol 36, 2018 (suppl; abstr 4047)


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown gastric adenocarcinoma not applicable Nivolumab + Ramucirumab Phase Ib/II Actionable In a Phase I/II trial, Cyramza (ramucirumab) and Opdivo (nivolumab) combination treatment resulted in a disease control rate of 59% (27/46) and partial response in 22% (10/46) of patients with previously treated advanced gastric adenocarcinoma, with a PD-L1 positive rate of 44% (J Clin Oncol 36, 2018 (suppl; abstr 4047); NCT02999295). detail...